Interleukin-22 enhances chemoresistance of lung adenocarcinoma cells to paclitaxel
- PMID: 32452013
- DOI: 10.1007/s13577-020-00373-3
Interleukin-22 enhances chemoresistance of lung adenocarcinoma cells to paclitaxel
Abstract
The chemoresistance of tumors is the main barrier to cancer treatment. Interleukin-22 (IL-22) plays an important role in the chemoresistance of multi-cancers; however, the roles of IL-22 in the paclitaxel resistance of lung adenocarcinoma cells remain to be investigated. The present study aims to investigate the potential mechanisms of IL-22 enhancing the chemoresistance of lung adenocarcinoma cells to paclitaxel. We cultured A549, H358, and A549/PTX cell lines. qRT-PCR and western blot assays were performed to examine the mRNA and/or protein levels of IL-22 in A549, A549/PTX, H358, and H358/PTX. Moreover, cells were transfected with IL-22 siRNA1, IL-22 siRNA2, and siRNA NC, and treated with paclitaxel, and the proliferation rate of lung adenocarcinoma cells was evaluated by MTT assay. Flow cytometry was conducted to determine the apoptosis rate of lung adenocarcinoma cells. The results showed that the expression of IL-22 in lung adenocarcinoma tissues was higher than that in normal tissues, and the expression of IL-22 was higher in A549/PTX and H358/PTX compared with A549 and H358 cells. Meanwhile, the expression of IL-22 was strongly correlated with smoking history and TMN stage, as well. Furthermore, IL-22 siRNA inhibited the proliferation and promoted the apoptosis of A549/PTX and H358/PTX cells, and IL-22 siRNA also suppressed the expression levels of AKT and Bcl-2 and increased the expression levels of Bax and cleaved caspase 3. To sum up, IL-22 may mediate the chemosensitivity of lung adenocarcinoma cells to paclitaxel through inhibiting the AKT signaling pathways.
Keywords: Apoptosis; Chemoresistance; IL-22; Lung adenocarcinoma; Proliferation.
References
-
- Kobayashi K, Naoki K, Manabe T, Masuzawa K, Hasegawa H, Yasuda H, Kawada I, Soejima K, Betsuyaku T. Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. Onco Targets Ther. 2018;11:3335–43. - PubMed - PMC - DOI
-
- Liu B, Qin J, Zhou J. Advances in the Treatment of relapsed small cell lung cancer. Chin J Lung Cancer. 2017;20(3):192–8. - DOI
-
- Lin D, Han X-G, Bing T, Wang M-Q, Qiao H, Zhang S-H, Fan Q-M. CXCR1/Akt signaling activation induced by mesenchymal stem cell-derived IL-8 promotes osteosarcoma cell anoikis resistance and pulmonary metastasis. Cell Death Dis. 2018;9(7):714. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
